Congenital erythropoietic porphyria (CEP) is an inborn error of heme biosynthesis characterized by uroporphyrinogen III synthase (UROS) deficiency resulting in deleterious porphyrin accumulation in blood cells responsible for hemolytic anemia and cutaneous photosensitivity. We analyzed here the molecular basis of UROS impairment associated with twenty nine UROS missense mutations actually described in CEP patients. Using a computational and biophysical joint approach we predicted that most disease-causing mutations would affect UROS folding and stability. Through the analysis of enhanced green fluorescent protein-tagged versions of UROS enzyme we experimentally confirmed these data and showed that thermodynamic instability and premature protein degradation is a major mechanism accounting for the enzymatic deficiency associated with twenty UROS mutants in human cells. Since the intracellular loss in protein homeostasis is in excellent agreement with the in vitro destabilization, we used molecular dynamic simulation to rely structural 3D modification with UROS disability. We found that destabilizing mutations could be clustered within three types of mechanism according to side chain rearrangements or contact alterations within the pathogenic UROS enzyme so that the severity degree correlated with cellular protein instability. Furthermore, proteasome inhibition using bortezomib, a clinically available drug, significantly enhanced proteostasis of each unstable UROS mutant. Finally, we show evidence that abnormal protein homeostasis is a prevalent mechanism responsible for UROS deficiency and that modulators of UROS proteolysis such as proteasome inhibitors or chemical chaperones may represent an attractive therapeutic option to reduce porphyrin accumulation and prevent skin photosensitivity in CEP patients when the genotype includes a missense variant. † These two authors contributed equally to this work as first co-authors. ‡ These two authors contributed equally to this work as senior co-authors.
Introduction
Congenital erythropoietic porphyria (CEP; OMIM 263700) or Gü nther's disease is a rare autosomal recessive disorder caused by deficient uroporphyrinogen III synthase (UROS, EC 4.2.1.75) enzymatic activity (1, 2) . UROS is the fourth enzyme of the heme biosynthetic pathway and catalyzes the rapid cyclization of the linear tetrapyrrole hydroxymethylbilane (HMB) to yield uroporphyrinogen isomer III (UROgenIII). The enzymatic defect is responsible for both the specific overproduction and diffuse body accumulation of the non-physiological and pathogenic isomers, uroporphyrin I (UROI) and coproporphyrin I (COPROI). UROI is a highly photocatalytic compound that accumulates in erythrocytes, liver, spleen and skin inducing hemolysis and skin photosensitivity after sunlight exposure. The clinical severity varies widely from minor skin photosensitivity to severe transfusion-dependent hemolytic anemia (3) . Classical treatments are unsatisfactory and only symptomatic (4) . To date, 49 different disease-causing mutations have been reported through the UROS gene on chromosome 10q25. 2-26.3 (http://www.hgmd.cf.ac.uk/ac/gene.php; date last accessed March 6, 2017) . Missense/nonsense mutations are predominant (29/49) but splicing defects (4/49), insertions/deletions (10/49) and mutations in the erythroid promoter or transacting eryrthroid-specific transcription factors (6/49) have also been described (5) . In diseases related to protein dysfunction, it is essential to understand the multiple mechanisms that explain the pathogenicity of specific mutants in order to provide the most effective therapeutic strategy. Missense mutations may reduce in vivo catalytic activity by directly altering enzymatic process but also by lowering enzyme folding and thermostability, which affects protein homeostasis (6) . In the cell, misfolded proteins are usually recognized by endoplasmic reticulum-associated quality control mechanisms and are degraded via the ubiquitin proteasome pathway (7) and others. In previous studies we have shown that two highly prevalent UROS missense mutations C73R and P248Q cause a loss of function as a result of protein misfolding while retaining significant intrinsic enzymatic activity (8) (9) (10) (11) . We demonstrated that C73R and P248Q mutants trigger premature degradation through the proteasome pathway in human erythroid cells that could be prevented by proteasome inhibitors. Interestingly, we obtained a reduced porphyrin accumulation as well as a reversion of the skin photosensitivity in CEP mice (Uros P248Q/P248Q ) treated with bortezomib, a clinically approved proteasome inhibitor (11) . In the present work, we examined the pathogenic feature of 29 missense mutations of the UROS gene previously described in CEP patients. Using four popular computational tools, we simulated the missense mutationsinduced change upon UROS protein stability with respect to the wild-type (WT) enzyme. We predicted that many UROS missense mutations would affect enzyme structure and decrease protein stability. We confirmed these hypotheses experimentally and showed both in vitro (tested over purified protein) and in human cells that most UROS missense mutations (20/29) lead to thermodynamic instability ultimately increasing protein turnover and premature UROS degradation. We performed molecular dynamic (MD) simulation on WT and mutant proteins under consideration to identify any changes in the local environment that might explain the deleterious protein unfolding. Three major types of structural alterations were identified: (type I) the new side chain creates additional contacts with nearby side chains while destroying interactions present in the WT core (type II), the mutation results in lost interactions and (type III) new interactions are formed, typically occurring when a bulky side chain replaces a smaller one and leads to steric hindrance. Interestingly, we show that significant UROS expression may be recovered after treatment with proteasome inhibitors in all unstable UROS mutants. Both experimental and computational data showed that impaired stability may be the main driving force rationalizing the intracellular UROS protein concentration. The mutants showing lower in vitro stability generally produce more contact alterations, and side chain rearrangements usually result in depleted enzyme concentrations. Furthermore, the premature degradation of misfolded UROS mutants by the proteasome pathway can be overcome by using clinically available proteasome inhibitors. These results pave the way for the development of a general therapeutic strategy aiming at up-regulating protein homeostasis by using inhibitors of UROS proteolysis or chemical chaperones that could promote and stabilize the folded conformation.
Results
Missense mutations of the UROS gene are predicted to disturb protein stability
We previously reported that C73R and P248Q mutations led to thermodynamic instability and premature degradation of UROS enzyme responsible for a profound deficiency of the catalytic activity in human cells that could be rescued by increasing proteostasis (9, 11) . We decided to expand our study and simulate the effect on UROS stability of every missense mutation described in CEP patients. We used four different web programs (SDM, I-mutant2, PoPMuSiC 2.1 and Eris server) to predict the thermostability changes, computed as DDG variations, caused by a single mutation in UROS protein. A previous study showed that this computational approach is well suited to predict protein stability and can be helpful to distinguish between disease-associated and non-disease variants (socalled neutral SNPs) (12) . The high resolution structure of human UROS enzyme [protein data bank (PDB) code 1JR2] (13) was used to computationally simulate mutant defects for each of the 29 UROS missense mutations retrieved in the literature and human gene MD (HGMD) (http://www.hgmd.cf.ac.uk/ac/ gene.php) (5) . Data from all experimentally tested mutations are shown in Table 1 . The cut-off values of DDG variations that would predict protein destabilization varies among the different web tools. Negative DDG values (kcal/mol) are related to protein stabilization whereas DDG ranges (0-1), (1-2), (2-3) and (>3) predicted mild, moderate, severe and dramatic protein destabilization, respectively. Nine disease-causing mutations were predicted to stabilize or mildly destabilize UROS protein by at least 3 web tools (L4F, A66V, E81D, V82F, A104V, D113V, H173Y, G225S and T228M). Seventeen UROS mutations are likely to affect UROS protein stability moderately or severely (V3F, Y19C, S47P, P53L, G58R, T62A, A69T, C73R, V99A, L139P,  Q187P, G188R, G188W, S212P, G236V, L237P and P248Q) . Finally, three mutations were predicted by most algorithms to affect protein stability dramatically (I129T, I219S and I255T). Interestingly, C73R and P248Q mutations were indeed associated with major protein instability, as confirmed by previously published experimental data (9, 11) . Taken together, the bioinformatic analyses suggest that 70% (20/29) of the missense mutations of the UROS gene described in CEP patients may affect protein folding causing instability. 2) confirmed that decreased mutant UROS expression is mainly because of enhanced proteolysis rather than transcription failure as previously described (9, 11) . For consistency, we also analyzed the outcome of EGFPtagged UROS mutant in HEK cells, which were transiently transfected with plasmids encoding C-terminal EGFP-tagged version of WT or mutant UROS enzyme. The level of fusion proteins was analyzed by fluorescence microscopy and Western blotting ( Fig. 1A and B, respectively) . C-terminal EGFP-UROS-tagged The change in folding free energy (DDG values, kcal/mol) was determined for each UROS mutant using SDM, I-mutant2, PopMusic and Eris algorithms to predict protein stability upon mutation. A positive DDG value indicates destabilizing mutations (0<DDG < 1 mild yellow, 1<DDG < 2 moderate orange, 2<DDG < 3 severe red, 3<DDG dramatic grey destabilization respectively), whereas stabilizing mutations exhibited negative DDG value (green). Expression of EGFP-UROS and UROS-EGFP proteins (represented as the % EGFP þ cells) were analyzed in stably transfected K562 erythroid cells. Results are expressed as mean 6 SD of 4 independent experiments.
version was preferred to the N-terminal construct for higher expression levels (11) . We observed the same distribution among UROS mutants as with K562 transfection experiments. Nine missense mutants (T62A, A66V, E81D, V82F, V99A, A104V, D113V, G225S, T228M) were associated with absent/moderate reduction of EGFP expression while 20/29 mutants showed severe/dramatic reduction in EGFP expression by fluorescence microscopy (Fig. 1A) . The level of the ectopically expressed proteins was analyzed by Western blotting (Fig. 1B) . As expected, EGFP fluorescence intensity observed by microscopy was correlated with EGFP immunodetection. The pEGFP-UROS vector expressed the selection marker neomycin phosphotransferase 2 (NPT2) which was detected at similar levels in transiently transfected HEK cells (Fig. 1B) .
In vitro kinetic stability correlates with mutant UROS intracellular content
To analyze in more detail and explain the various protein contents observed for the set of mutants, we investigated protein stability in vitro. As previously shown, UROS conformation can be described by a kinetic stability model, where the native state (N) spontaneously converts into a more stable (yet inactive) conformation (F) (10, 14) . Adding to previously described results, isothermal unfolding kinetics monitored by circular dichroism has been measured for all the described CEP-causing mutations. Kinetic stability can be quantified by the apparent rate (k app ), which takes the general form (15):
where k NU ; k UN and k UF are the exchange rates between the native (N), unfolded (U) and final/inactive (F) states. It has been shown that the apparent rate for UROS is equivalent to the unfolding rate (k app % k NU ) and is therefore a good reporter of the kinetic stability of the protein. The unfolding rates of the 29 UROS mutants (reported as a fraction of the WT E a value, g) were plotted as a function of the intracellular UROS-EGFPtagged protein content (%EGFP þ K562 cells) (Fig. 2) . Remarkably, the kinetic stability data, measured in vitro, agrees well with the intracellular protein homeostasis: the mutants with the highest amounts in the cytosol also show enhanced kinetic stability. These results confirmed (i) that a majority of UROS mutants are kinetically driven and, more importantly, (ii) the intracellular protein content (as measured in cellulo) can be qualitatively rationalized in terms of in vitro stability. 
Structural basis for UROS unfolding upon mutation
To gain insight into the mechanism of UROS unfolding upon mutation, we carried out MD simulations. Specifically, we performed MD simulations in an explicit solvent (40 ns, see Materials and Methods) for WT UROS as well as for the mutant set under consideration. For all the mutant proteins but five (E81D, H173Y, G188R, G188W and G236V) the calculations were able to identify changes in the local mutation environment. Such variations are shown in the contact maps (Supplementary Material, Fig. S1 ), which also indicate that the incipient dynamic changes are mostly located near to mutation sites. Contacts created and/or destroyed with respect to an equivalent MD performed over WT UROS are used as a stability descriptor of the trajectories (Table 2 ). According to this analysis (Supplementary Material, Fig. S1 ) mutants can be clustered in three main mechanisms ( Fig. 3 ): (i) side chain rearrangements (type I), where the mutated side chain creates new contacts with nearby residues while it destroys former interactions present in the WT core. V3F and V82F, classified as type I in Table 2 , are representative examples for this destabilization mechanism.
(ii) Local unfolding (type II), where the mutation produces only the loss of interresidue contacts, ultimately resulting in the local unfolding of the protein (ex. Y19C, V99A and P248Q) and (iii) steric hindrance (type III) where the interactions with nearby residues are raised because the mutation results in a bulkier side chain (ex. C73R, S212P and T228M) (14) . Thus, MD simulations provide useful information for understanding the structural impairment produced upon mutation. Of note, reduced intracellular UROS content could be exacerbated by the loss of contact alterations and chain rearrangements which contributed to cell clearance.
Premature intracellular degradation of missense UROS mutants can be rescued by proteasome inhibitors
We have previously demonstrated that proteasome inhibition may partially prevent premature degradation of C73R and P248Q in vitro (9, 11) . Furthermore, we showed a significant reduction in porphyrin accumulation as well as skin photosensitivity in CEP mice treated with a clinically approved proteasome inhibitor (Bortezomib) (11) . We herein report that thermodynamic instability and enhanced proteolysis seem to be a common pathophysiological mechanism leading to premature degradation for most (20/29) UROS missense mutants. We wondered whether therapeutic proteasome inhibition could be extended to additional UROS missense mutations. Stably transfected K562 cells and transiently transfected HEK cells expressing EGFP-UROS or UROS-EGFP-tagged protein were incubated with proteasome (i.e. MG132 and bortezomib) or lysosome (bafilomycin) inhibitors (Figs 1 and 4) and EGFP-tagged protein expression was analyzed by flow cytometry, fluorescence microscopy and Western blotting. As expected, a minimally increased expression of WT and stable/moderately destabilized UROS mutants (T62A, A66V, E81D, V82F, V99A, A104V, D113V, G225S, T228M) expression was observed in both HEK (Fig. 1 ) and K562 cells (Fig. 4) after incubation with lysosome inhibitors. On the other hand, although inhibition of the endosomallysosomal pathway did not significantly increase ectopic protein expression, proteasome inhibitors dramatically improved the retention of all unstable EGFP-tagged UROS missense mutants ( Fig. 4 and Supplementary Material, Fig. S2 ). We then analyzed EGFP-tagged UROS expression in stably transfected K562 cells by semi-quantitative RT-PCR. We found a relative fold increase of 2.22 6 0.6 of EGFP-UROS mRNA expression upon proteasome inhibitor treatment. These results confirm that protein stabilization is the main mechanism of mutant UROS rescue as previously described (9, 11) . Taken together, they suggest that proteasome inhibition may become a therapeutic option for many CEP patients harboring destabilizing UROS missense mutations.
Discussion
CEP is a rare genetic disease characterized by markedly decreased uroporphyrinogen III synthase (UROS) activity. Whereas mutations are spread along the UROS gene, missense mutations are predominant and UROS C73R is present in about one-third of all reported cases (2,5). The Human Genome Mutation Database contains at present more than 100 000 entries for mutations responsible for genetic diseases, and missense/nonsense mutations represent more than half of them. In the last decade, protein misfolding induced by missense mutations has been demonstrated to be the seminal molecular mechanism in a growing number of inborn errors of metabolism, resulting in early degradation by the cellular protein quality control system or mis-trafficking and ultimately leading to protein loss-offunction (6, 16) . A missense mutation that affects the folded conformation and alters the stability or binding affinity of a protein complex may cause significant perturbations or complete abolishment of the function of that particular protein. This is of particular importance in CEP since UROS is a thermolabile enzyme undergoing irreversible denaturation (8) . When irreversible denaturation occurs, the free energy difference upon unfolding cannot be used to estimate the protein concentration since stability of the folded conformation is ultimately controlled by the unfolding kinetics (kinetic stability) (14) . Nevertheless, under these conditions, the changes in the folding free energy upon mutation (DDG) are still a bona fide descriptor of the destabilization energetics, and DDG is used here to quantify the magnitude of a mutation's effect on stability. In a first step, we used four different computational methods to predict the effect of mutations on stability and folding free energy (energy difference between folded and unfolded states). This strategy was successfully applied to predict the effect of mutations on protein stability, conformational dynamic and enzymatic activity in the context of genetic diseases (12) . Various factors may influence prediction accuracy including the type of substituted amino acid, protein structural class and flexibility, structural environment of an affected site. All these factors should be considered when judging the effectiveness of a given approach. The Site Directed Mutator (SDM) method relies on structural information and uses a statistical potential energy function to predict DDG (17). I-Mutant2.0 and PoPMuSIC-2.0 methods are machinelearning approaches based on data relevant to protein stability, temperature, salt concentration and pH values (18, 19) . IMutant2.0 uses support vector machines and makes prediction based on either structure or sequence alone. ERIS method uses structural information and applies medusa force field while including backbone flexibility to make prediction (20) . The cut-off values for DDG corresponding to stabilizing or destabilizing mutations may vary between the different algorithms. By considering DDG < 0 kcal/mol as stabilizing and DDG> 2 kcal/mol as destabilizing thresholds, we predicted that 20/29 UROS missense mutations may affect protein folding and lead to instability. In any case, the fact that computational predictors are DDGbased suggests that the enthalpic component may play a significant role in mutant-induced UROS destabilization. Consistently, thorough analysis of our MD simulations properly identified the interactions that are lost or created upon mutation ( Fig. 3 and Supplementary Material, Fig. S1 ). Three different mechanisms were observed, type II being the most frequent (10/29 mutants). This is not surprising since protein folding has been shaped by evolution to optimize interactions in order to minimize frustration and the introduction of a new side chain will likely destroy such delicate interplay (21) . In fact, bond impairment is sufficient to explain the reduced homeostasis for seven mutations while three mutants undergoing type II kinetic stabilization (T62A, V99A, G225S) still retain their UROS intracellular concentration, underlining the fact that the energy of the lost interactions (and not their number) is the crucial stability reporter. Steric hindrance (type III) is more frequently found (7/29 mutants) than side chain rearrangements (4/29 mutants) but both mechanisms are effective in destabilizing UROS, almost always leading to drastic decreased in the protein's homeostasis. Finally, MD simulations are also able to predict minimal changes for some mutants that also showed intracellular expression comparable to WT (i.e. E81D, A104V). We previously analyzed in vitro the unfolded kinetics and the relative enzymatic-specific activity of WT and 25 missense UROS mutants purified from prokaryotic expression assays (8) . While most UROS mutants retained significant kinetic stability (>30% versus WT), evidence showed that a mutant subset (A66V, H173Y, I219S and L237P) harbored accelerated protein unfolding. On the other hand, several UROS mutants (E81D, V82F, V99A, A104V and T228M) retained very high enzymatic activity and showed no decrease in stability. The present study was designed as an exhaustive in cellulo analysis of all missense mutations using UROS mutants fused to EGFP in a reporter fluorescence assay. We found a strong correlation between unfolded kinetics and UROS mutant protein expression in the erythroid cell line K562 (Fig. 2) . These results suggest that UROS mutant instability is the main mechanism leading to increased protein turnover in vivo. For three mutants (L4F, V99A and H173Y), we observed a discrepancy between the computational prediction of protein stability and the experimental data (in vitro and in cellulo). Although the V99A UROS mutant was predicted to be destabilized by most web systems, both normal unfolded kinetic and cellular expression were observed. On the other hand, L4F and H173Y mutants were predicted to be poorly destabilized while we observed a decrease in both unfolded kinetic and cellular expression for these two UROS mutants. These discrepancies suggest that various combinations of subtle mechanisms are involved in thermodynamic instability. Finally, T62A is a case where mutation produces a decrease in catalytic activity that is not accompanied by a loss in stability/ homeostasis (Fig. 2) . Analysis of the MD trajectory (Supplementary Material, Fig. S1 ) reveals that the mutation affects some residues in the substrate binding site (A122, P152, E149) (22) , likely affecting the KM of the enzyme.
Concerning the C73R mutation, we previously reported that the loss in stability was produced by the steric clash between the bulky arginine side chain and the nearby atoms (23) . Using a second site mutation strategy, we successfully rescued the UROS C73R enzymatic activity and partially recovered kinetic stability, highlighting the importance of the interaction network in UROS stability (23) . Because UROS is a single polypeptide chain organized as a bi-domain protein, the composition and structure of the hinge is essential for its kinetic stability. In fact, the inter-domain closure angle plays a direct functional role since the two domains need to be close together in order to catalyze the polypyrrole condensation with inversion of configuration in the D-ring. Analysis of the MD trajectories (Supplementary Material, Fig. S1 ) showed that some of the mutants (Y19C, T62A, A66V, P248Q and to some extent P53L and I129S) induce inter-domain closure in the absence of substrate, which may alter the protein's stability and/or direct catalytic activity. This mechanism is also compatible with the loss of homeostasis observed in G188W, while we observed a drastic change in the inter-domain reorientation without rearrangement in the local mutation environment. We found that nine UROS mutants were, at the most, only mildly destabilized (T62A, A66V, E81D, V82F, V99A, A104V, D113V, G225S, T228M) while they retained significant residual enzymatic-specific activity (ESA) in vitro (32-100% of WT) except for T62A (1.2%) ( Table 3 ) (8). These findings raise questions of a putative pathogenicity in CEP patients. Most of these patients harbor UROS compound heterozygous and have highly destabilized mutant on the second allele (Table 3 ). Because most of these patients have a mild cutaneous phenotype, we hypothesize that these mutants play a moderately pathogenic role and that protein destabilization accounts largely for the pathogenicity of UROS mutants (Table 3) . Concerning T62A mutation, this mutation was described in a CEP patient exhibiting a mild cutaneous phenotype and harboring a non-sense mutation (N249X) on the second UROS allele. As previously discussed, T62A exhibited reduced enzymatic-specific activity (1% versus WT) whereas thermodynamic stability was conserved in vitro and in cellular experiments. Mild features of CEP disease have been described in a male patient hemizygous for a GATA1 gene defect (c.646C>T, p.Arg216Val associated with dyserythropoietic thrombocytopenia) and a novel missense mutation of UROS gene (D113V). The pathogenicity of these UROS variant remains elusive since the residue is not conserved among species and has been reported in control populations (24) . Furthermore, the prediction software Polyphen and Mutation Taster, implemented through Alamut (Interactive Biosoftwares), predicted this variant as probably non-pathogenic. Some patients harboring stable mutant (ex. G225S and T228M) developed a severe phenotype and especially transfusion-dependent hemolytic anemia. Phenotypic variability has already been reported in patients harboring the same gene defect and the recent description of ALAS2 gain-of-function mutations as an aggravating factor underscores the possible implication of modifier genes underlying the CEP disease phenotype (25) .
Proteostasis regulators including proteasome inhibitors have proven effective in restoring mutant enzyme homeostasis and can be used either alone or in combination with chaperones to obtain synergistic effects. We recently demonstrated that C73R and P248Q UROS mutants retained significant enzymatic activity but triggered premature degradation as a consequence of protein misfolding in erythroid cells, which could be prevented by proteasome inhibitors (11) . This therapeutic approach is particularly attractive because we demonstrate here that a majority of UROS missense mutations lead to increased protein turnover while most of the mutants retained significant intrinsic enzymatic activity (8) . We demonstrate here that the proteasome inhibition using bortezomib, a clinically approved drug, partially rescued the premature degradation of every unstable UROS mutant. Second-generation proteasome inhibitors have been developed that are potentially more effective and available for oral administration (33) . Our results argue in favor of their evaluation in clinical practice for CEP patients harboring destabilizing UROS mutants. To overcome the potentially harmful effects of proteasome inhibition, pharmacological chaperones constitute a fresh alternative. Such small molecules are able to bind specifically and rescue misfolded proteins by conformational stabilization, thereby preventing early degradation and allowing proper cellular trafficking and localization. Pharmacological chaperones have been successfully evaluated in numerous inherited genetic diseases (6, 16, 34) . High-throughput screening exploring libraries of chemicals and drugs may allow the identification of UROS-stabilizing compounds and constitute a new line of treatment for CEP.
In summary, we have demonstrated that protein instability is the leading mechanism associated with pathogenic missense mutations of the UROS gene and have provided an atomic description of the destabilization mechanism. These results are potentially valid for numerous diseases since protein stability is one of the most delicate and fragile features shaped by natural evolution. Thus, this study highlights the potential therapeutic benefit to be gained from proteasomal inhibition or consequently from pharmacological chaperones in the treatment of rare diseases, as exemplified by the UROS gene defect of the heme biosynthetic pathway.
Materials and methods
In silico analysis of UROS mutation-induced change in protein stability
Each mutant structure was submitted to four different web servers to predict the mutation-induced change in protein stability with respect to the WT enzyme: SDM (17), I-mutant2 (18), PoPMuSiC (19) and ERIS (20) . These servers use different criteria to evaluate the impact of mutations on protein stability. The Eris server calculates the change in protein stability induced by mutations by utilizing the recently developed Medusa atomicmodeling suite. PoPMuSiC uses linear combinations of database-derived potentials, whose coefficients depend on the solvent accessibility of the mutated residues. By analogy with the folding-unfolding cycle, the SDM algorithm uses a set of conformationally constrained environment-specific substitution tables to calculate the difference in the stability scores of the folded and unfolded state for the WT and mutant protein structures. I-mutant2.0 is a web server for the automatic prediction of protein stability changes upon single-site mutations that was derived from PoTherm (18) . We computed the variation in the folding free energy (DDG) of the UROS mutants: destabilizing mutations exhibited positive DDG while stabilizing mutations were associated with negative DDG.
DNA constructs
We generated mammalian expression plasmids encoding human UROS cDNA (WT and mutants) fused to the C-terminus or N-terminus end of EGFP cDNA in pEGFP-C3 vector or pEGFP-N1, respectively (Promega, Inc., USA) as described previously (11) .
Cell culture, transfection and generation of stably transfected mammalian cell lines 
Treatment with lysosomal or proteasome inhibitors
Stably transfected K562 cells were cultured for 16 h in the presence of the proteasome inhibitors MG132 10 lM (Sigma-Aldrich, USA) or bortezomib 100 nM (Velcade V R ), the lysosomal inhibitor bafilomycin 20 mM (Sigma-Aldrich) or di-methyl-sulfoxide (DMSO) 0.1% (Sigma-Aldrich) as a control. Thirty-six hours after transfection, HEK cells were treated with 100 nM bortezomib or DMSO 0.1% for 16 additional hours. Cells were analyzed by epifluorescence microscopy.
Flow cytometry analysis
Flow cytometry analyses were performed on a FACScanto II analyser (BD Biosciences) and EGFP-tagged UROS protein expression was detected using the FL-1 channel (excitation wavelength 488 nm).
Western blot analysis and antibodies
For western blotting, equal amounts (20 lg) of protein were separated by SDS-PAGE (sodium-dodecyl-sulfate polyacrylamide gel electrophoresis) electrophoresis and PVDF membranes were probed with rabbit polyclonal anti-EGFP (Santa Cruz, clone 9996). The expression of the selection marker neomycin phosphotransferase 2 (NPT2) was analyzed using mouse monoclonal anti-NPT2 (Abcam, clone 4B4D1). Glyceraldehyde-3-phosphate deshydrogenase (GAPDH) expression was detected with rabbit polyclonal anti-GAPDH (cell signaling, clone 14C10) and used to control protein loading in Western Blot analyses. The signal was revealed with horseradish peroxidase-linked secondary antibody and visualized using the Enhanced ChemiLuminescence Kit according to the manufacturer's instructions (ECL prime reagent, Amersham). Enzyme-specific activity (ESA) as previously described (8) .
RT-PCR analysis of EGFP-UROS expression in K562 cells
A quantitative real-time PCR assay was used to quantify EGFP-UROS mRNA in stably transfected K562 cells. The relative expression was normalized to endogenous GAPDH mRNA. Primers used were as follows: for EGFP-UROS: forward 5'-GTCCTGC TGGAGTTCGTGA-3'; reverse 5'-ACTGCTCTGGGGCTGGTAA and UROS-EGFP: forward 5-AGTCCCTCTGGCCTCACATAC-3 and reverse 5-CCGGACACGCTGAACTTG-3; for human GAPDH: forward 5-CCATCTTCCAGGAGCGAG-3and reverse 5-GAGATGATG ACCCTTTTGGC-3.
Prokaryotic UROS expression and sample preparation
Freshly transformed E. coli BL21 (DE3) cells were used for protein expression. UROS (WT and mutants, MW %31.1 kDa) was purified according to the following protocol: the cell pellet (1 l of culture) was resuspended in 20 mL of buffer A (20 mM sodium phosphate, 500 mM NaCl, 5 mM imidazole, pH 7.4) and thoroughly sonicated. The supernatant was mixed with 3 mL of HisTag resin (Ni-NTA V C , Invitrogen) and eluted with buffer A containing 500 mM of imidazole. The proteins were further purified by size exclusion chromatography (Superdex 
Circular dichroism measurements
All experiments were collected in a JASCO J-810 spectropolarimeter using a 0.2-cm path length quartz cuvette. Sample concentration was 5 lM for all the proteins tested. The isothermal unfolding rate (k NU ) was determined for each of the UROS mutants in a [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] C range (at least four measures) whereas seven different temperatures were used to characterize the WT (37, 40, 42, 44, 46 , 48, 50 C). Freshly purified samples at 4 C were transferred to the spectropolarimeter, pre-stabilized to the target temperature, and maintained at constant temperature until the decay reached a plateau. Typical decay times lasted from two hours (at 50 C) to 3 days (at 41 C) with variations linked to the activation energy barrier (E a ) were observed. The time constant (k app ) was extracted from the decay over time of the signal at 222 nm and linear dependence of the log(k app ) with T (Arrhenius model) was assumed to estimate the activation-free energy. The g parameter expressed as percentage was defined as the ratio of E a (WT) to E a (Mut) for a given UROS mutant.
Molecular dynamic simulations for UROS WT and UROS mutants
The crystal structure of human uroporphyrinogen III synthase was used for MD simulations (PDB: 1JR2, chain A) (13). The atomic structure was then solvated in a rectangular water box of dimensions 65.4 Â 77.3 Â 94.3 Å 3 using the Solvate plug-in of VMD (35) . Na þ and Cl -ions were added to the system to achieve charge neutralization up to a final concentration of 150 mM. The resulting system comprised $44 100 atoms. The CHARMM 36 force field was employed to describe the molecular mechanics (36) . The TIP3P model was used for water (37) . The standard CHARMM parameters were used for ions (38) . NAMD version 2.10 was used for all calculations. Following 20 000 steps of energy minimization, the atomic system was equilibrated for 1 ns. The pressure was kept constant at 1 atm by the Nosé -HooverLagevin piston, with a damping time constant of 50 ps and a period of 100 ps (39) . The temperature was maintained at 298 K by coupling the system to a Langevin thermostat, with a sampling coefficient of 1 ps À1 . The particle mesh Ewald (PME) algorithm was used evaluate electrostatic interactions beyond 12 Å , with a PME grid spacing of 1 Å , and NAMD defaults for spline and OE values (40) . A cut-off at 12 Å was applied to non-bonded forces, and both electrostatics and van der Waals forces were smoothly switched off between the cut-off distance of 12 Å and the switching distance of 19 Å , using the default NAMD switching function. A Verlet neighbor list with pair-list distance of 14 Å was used to evaluate non-bonded neighboring forces within the pair-list distance (41) . The lengths of covalent bonds involving hydrogen atoms were constrained by the SETTLE algorithm in order to be able to use a 2-fs time step (42) . The multiple time step algorithm Verlet-I/r-RESPA was used to integrate the equations in motion (41, 43) . Non-bonded short-range forces were computed for each time step while long range electrostatic forces were updated every two time steps. Simulation for WT UROS was run for 40 ns. Atomic coordinates were collected every 10 000 steps. During this trajectory, an equilibrated atomic structure was selected. Based on this WT structure up to 30 different mutants were introduced using PyMOL mutagenesis toolbox (The PyMOL Molecular Graphics System, Version 1.8 Schrö dinger, LLC). Mutated UROS proteins were used as initial structures for new simulations. MD for mutants were performed as before but they were run for 20 ns. The MD trajectories were analyzed using VMD (35) . All the residues making contacts below 4 Å from the mutated residues were annotated during the trajectory. Contact-percentage was obtained by dividing the number of contacts observed by the total number of frames in the trajectory. UROS mutant contactpercentages were compared with the same residue number in the WT protein (using a cutoff of 25% of the frames showing differences between the two simulations). This method allowed us to monitor new or lost contacts.
Statistical analysis
Non-parametric Mann-Whitney tests were used owing to the small sample size. Statistical significance was set at P < 0.05. Data are mean 6 SD of four independent experiments.
Supplementary Material
Supplementary Material is available at HMG online.
